股本结构
单位：万股
| 公告日期 | 2025-02-04 | 2025-01-27 | 2025-01-21 | 2025-01-15 | 2025-02-05 | 2024-12-20 |
|---|---|---|---|---|---|---|
| 证券总股本 | 443905.28 | 443963.43 | 444016.41 | 444066.21 | 446500.00 | 444134.05 |
| 普通股本 | 443905.28 | 443963.43 | 444016.41 | 444066.21 | 446500.00 | 444134.05 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-02-03 | 2025-01-24 | 2025-01-17 | 2025-01-10 | 2024-12-31 | 2024-12-19 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：1
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-02-04 | 443905.28 | 未披露 | 定期报告 | 2025-02-03 |
| 2025-01-27 | 443963.43 | 未披露 | 定期报告 | 2025-01-24 |
| 2025-01-21 | 444016.41 | 未披露 | 定期报告 | 2025-01-17 |
| 2025-01-15 | 444066.21 | 未披露 | 定期报告 | 2025-01-10 |
| 2025-02-05 | 446500.00 | 未披露 | 定期报告 | 2024-12-31 |
| 2024-12-20 | 444134.05 | 未披露 | 定期报告 | 2024-12-19 |
| 2024-12-16 | 444165.64 | 未披露 | 定期报告 | 2024-12-09 |
| 2024-12-09 | 444203.74 | 未披露 | 定期报告 | 2024-12-06 |
| 2024-12-02 | 444242.83 | 未披露 | 定期报告 | 2024-11-29 |
| 2024-11-25 | 444282.04 | 未披露 | 定期报告 | 2024-11-22 |
| 2024-11-18 | 444322.04 | 未披露 | 定期报告 | 2024-11-18 |
| 2024-11-08 | 444365.15 | 未披露 | 定期报告 | 2024-11-08 |
| 2024-10-28 | 445007.42 | 未披露 | 定期报告 | 2024-10-25 |
| 2024-10-21 | 445030.77 | 未披露 | 定期报告 | 2024-10-18 |
| 2024-10-15 | 445053.77 | 未披露 | 定期报告 | 2024-10-11 |
| 2024-10-07 | 445077.47 | 未披露 | 定期报告 | 2024-10-04 |
| 2024-09-30 | 445100.02 | 未披露 | 定期报告 | 2024-09-27 |
| 2024-09-24 | 445120.61 | 未披露 | 定期报告 | 2024-09-20 |
| 2024-09-16 | 445143.61 | 未披露 | 定期报告 | 2024-09-13 |
| 2024-09-09 | 445164.81 | 未披露 | 定期报告 | 2024-09-06 |
| 2024-09-09 | 445186.01 | 未披露 | 定期报告 | 2024-08-30 |
| 2024-08-26 | 445206.41 | 未披露 | 定期报告 | 2024-08-23 |
| 2024-08-19 | 445226.91 | 未披露 | 定期报告 | 2024-08-16 |
| 2024-08-12 | 445245.99 | 未披露 | 定期报告 | 2024-08-09 |
| 2024-08-06 | 445256.71 | 未披露 | 定期报告 | 2024-08-05 |
| 2024-07-29 | 445281.37 | 未披露 | 定期报告 | 2024-07-26 |
| 2024-07-22 | 445301.52 | 未披露 | 定期报告 | 2024-07-19 |
| 2024-07-15 | 445320.21 | 未披露 | 定期报告 | 2024-07-12 |
| 2024-07-09 | 445338.78 | 未披露 | 定期报告 | 2024-07-05 |
| 2024-07-02 | 445357.28 | 未披露 | 定期报告 | 2024-06-28 |
| 2024-06-24 | 445375.01 | 未披露 | 定期报告 | 2024-06-21 |
| 2024-06-17 | 445393.11 | 未披露 | 定期报告 | 2024-06-14 |
| 2024-06-10 | 445411.36 | 未披露 | 定期报告 | 2024-06-07 |
| 2024-06-03 | 445426.76 | 未披露 | 定期报告 | 2024-05-31 |
| 2024-05-28 | 443596.40 | 未披露 | 定期报告 | 2024-05-27 |
| 2024-05-17 | 443615.82 | 未披露 | 定期报告 | 2024-05-16 |
| 2024-05-01 | 444255.43 | 未披露 | 定期报告 | 2024-04-30 |
| 2024-04-22 | 446132.58 | 未披露 | 定期报告 | 2024-04-19 |
| 2024-04-17 | 446153.28 | 未披露 | 定期报告 | 2024-04-12 |
| 2024-04-08 | 446174.28 | 未披露 | 定期报告 | 2024-04-05 |
| 2024-04-02 | 446190.88 | 未披露 | 定期报告 | 2024-03-27 |
| 2024-04-01 | 446202.98 | 未披露 | 定期报告 | 2024-03-22 |
| 2024-03-18 | 446222.93 | 未披露 | 定期报告 | 2024-03-15 |
| 2024-03-11 | 446242.78 | 未披露 | 定期报告 | 2024-03-08 |
| 2024-03-04 | 446263.48 | 未披露 | 定期报告 | 2024-03-01 |
| 2024-02-22 | 446306.48 | 未披露 | 定期报告 | 2024-02-16 |
| 2024-02-13 | 446328.03 | 未披露 | 定期报告 | 2024-02-09 |
| 2024-01-30 | 445612.19 | 未披露 | 定期报告 | 2024-01-29 |
| 2024-01-22 | 445677.28 | 未披露 | 定期报告 | 2024-01-19 |
| 2024-01-16 | 445731.28 | 未披露 | 定期报告 | 2024-01-12 |
| 2024-01-08 | 445783.79 | 未披露 | 定期报告 | 2024-01-05 |
| 2024-01-31 | 451000.00 | 未披露 | 定期报告 | 2023-12-31 |
| 2023-12-22 | 445828.79 | 未披露 | 定期报告 | 2023-12-21 |
| 2023-12-19 | 445875.79 | 未披露 | 定期报告 | 2023-12-15 |
| 2023-12-11 | 445933.29 | 未披露 | 定期报告 | 2023-12-08 |
| 2023-12-05 | 445989.29 | 未披露 | 定期报告 | 2023-12-01 |
| 2023-11-28 | 446044.99 | 未披露 | 定期报告 | 2023-11-24 |
| 2023-11-21 | 446099.99 | 未披露 | 定期报告 | 2023-11-17 |
| 2023-11-14 | 446155.44 | 未披露 | 定期报告 | 2023-11-10 |
| 2023-11-01 | 446884.82 | 未披露 | 定期报告 | 2023-10-31 |
| 2023-10-23 | 446980.32 | 未披露 | 定期报告 | 2023-10-20 |
| 2023-10-10 | 447124.82 | 未披露 | 定期报告 | 2023-10-06 |
| 2023-10-02 | 447199.82 | 未披露 | 定期报告 | 2023-09-29 |
| 2023-09-26 | 447274.72 | 未披露 | 定期报告 | 2023-09-22 |
| 2023-09-13 | 447390.26 | 未披露 |
更多>>
As communicated on 10 August 2023 in connection with the release of Novo Nordisk's financial results for the first six months of 2023, Novo Nordisk's Board of Directors has approved a split of the trading units of the Novo Nordisk B shares listed on Nasdaq Copenhagen and of the American Depositary Receipts (ADRs) listed on New York Stock Exchange (NYSE) in a two-for-one ratio.
|
2023-09-20 |
| 2023-09-13 | 223695.13 | 未披露 | 定期报告 | 2023-09-12 |
| 2023-09-05 | 223746.13 | 未披露 | 定期报告 | 2023-08-28 |
| 2023-08-28 | 223784.14 | 未披露 | 定期报告 | 2023-08-25 |
| 2023-08-22 | 223822.44 | 未披露 | 定期报告 | 2023-08-18 |
| 2023-08-09 | 223872.78 | 未披露 | 定期报告 | 2023-08-08 |
| 2023-07-31 | 223936.55 | 未披露 | 定期报告 | 2023-07-28 |
| 2023-07-24 | 223980.20 | 未披露 | 定期报告 | 2023-07-21 |
| 2023-07-17 | 224023.60 | 未披露 | 定期报告 | 2023-07-14 |
| 2023-07-10 | 224067.65 | 未披露 | 定期报告 | 2023-07-07 |
| 2023-07-03 | 224110.95 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-06-26 | 224154.99 | 未披露 | 定期报告 | 2023-06-23 |
| 2023-06-21 | 224199.19 | 未披露 | 定期报告 | 2023-06-16 |
| 2023-06-12 | 224242.49 | 未披露 | 定期报告 | 2023-06-09 |
| 2023-06-06 | 224276.74 | 未披露 | 定期报告 | 2023-05-30 |
| 2023-05-30 | 224352.21 | 未披露 | 定期报告 | 2023-05-22 |
| 2023-05-16 | 224376.61 | 未披露 | 定期报告 | 2023-05-12 |
| 2023-05-10 | 224394.44 | 未披露 | 定期报告 | 2023-05-09 |
| 2023-05-03 | 224745.06 | 未披露 | 定期报告 | 2023-05-02 |
| 2023-04-26 | 224800.57 | 未披露 | 定期报告 | 2023-04-24 |
| 2023-04-17 | 224839.77 | 未披露 | 定期报告 | 2023-04-14 |
| 2023-04-13 | 224897.72 | 未披露 | 定期报告 | 2023-03-27 |
| 2023-03-27 | 224937.50 | 未披露 | 定期报告 | 2023-03-24 |
| 2023-03-20 | 224982.85 | 未披露 | 定期报告 | 2023-03-17 |
| 2023-03-13 | 225028.35 | 未披露 | 定期报告 | 2023-03-06 |
| 2023-03-06 | 225073.13 | 未披露 | 定期报告 | 2023-02-27 |
| 2023-02-27 | 225117.10 | 未披露 | 定期报告 | 2023-02-24 |
| 2023-02-22 | 225180.96 | 未披露 | 定期报告 | 2023-02-16 |
| 2023-02-07 | 225245.10 | 未披露 | 定期报告 | 2023-02-06 |
| 2023-01-31 | 224836.85 | 未披露 | 定期报告 | 2023-01-31 |
| 2023-01-23 | 224875.69 | 未披露 | 定期报告 | 2023-01-23 |
| 2023-02-01 | 228000.00 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Purchase of treasury shares
Reduction of the B share capital
|
2022-12-31 |
| 2022-12-22 | 224989.61 | 未披露 | 定期报告 | 2022-12-21 |
| 2022-12-20 | 225012.19 | 未披露 | 定期报告 | 2022-12-16 |
| 2022-12-05 | 225089.11 | 未披露 | 定期报告 | 2022-12-02 |
| 2022-11-21 | 225171.72 | 未披露 | 定期报告 | 2022-11-18 |
| 2022-11-14 | 225214.62 | 未披露 | 定期报告 | 2022-11-11 |
| 2022-11-01 | 225676.44 | 未披露 | 定期报告 | 2022-10-24 |
| 2022-10-24 | 225729.45 | 未披露 | 定期报告 | 2022-10-21 |
| 2022-10-17 | 225773.45 | 未披露 | 定期报告 | 2022-10-10 |
| 2022-10-11 | 225816.33 | 未披露 | 定期报告 | 2022-10-03 |
| 2022-10-06 | 225862.33 | 未披露 | 定期报告 | 2022-09-30 |
| 2022-09-26 | 225908.75 | 未披露 | 定期报告 | 2022-09-23 |
| 2022-09-06 | 226042.75 | 未披露 | 定期报告 | 2022-09-02 |
| 2022-08-29 | 226086.68 | 未披露 | 定期报告 | 2022-08-26 |
| 2022-08-22 | 226129.68 | 未披露 | 定期报告 | 2022-08-19 |
| 2022-08-22 | 226174.68 | 未披露 | 定期报告 | 2022-08-12 |
| 2022-08-03 | 226235.26 | 未披露 | 定期报告 | 2022-08-02 |
| 2022-07-25 | 226296.86 | 未披露 | 定期报告 | 2022-07-22 |
| 2022-07-18 | 226341.36 | 未披露 | 定期报告 | 2022-07-15 |
| 2022-07-18 | 226388.85 | 未披露 | 定期报告 | 2022-07-08 |
| 2022-07-18 | 226434.35 | 未披露 | 定期报告 | 2022-07-01 |
| 2022-06-27 | 226480.36 | 未披露 | 定期报告 | 2022-06-24 |
| 2022-06-21 | 226526.86 | 未披露 | 定期报告 | 2022-06-17 |
| 2022-06-13 | 226571.86 | 未披露 | 定期报告 | 2022-06-10 |
| 2022-06-13 | 226607.86 | 未披露 | 定期报告 | 2022-06-03 |
| 2022-05-31 | 226654.36 | 未披露 | 定期报告 | 2022-05-25 |
| 2022-05-23 | 226683.36 | 未披露 | 定期报告 | 2022-05-20 |
| 2022-05-24 | 226730.36 | 未披露 | 定期报告 | 2022-05-12 |
| 2022-05-04 | 226790.78 | 未披露 | 定期报告 | 2022-05-03 |
| 2022-05-03 | 227211.53 | 未披露 | 定期报告 | 2022-05-02 |
| 2022-04-25 | 227263.47 | 未披露 | 定期报告 | 2022-04-22 |
| 2022-04-11 | 227325.16 | 未披露 | 定期报告 | 2022-04-08 |
| 2022-03-14 | 227518.47 | 未披露 | 定期报告 | 2022-03-11 |
| 2022-03-07 | 227571.97 | 未披露 | 定期报告 | 2022-03-04 |
| 2022-02-28 | 227625.47 | 未披露 | 定期报告 | 2022-02-21 |
| 2022-02-22 | 227679.97 | 未披露 | 定期报告 | 2022-02-18 |
| 2022-02-10 | 227786.45 | 未披露 | 定期报告 | 2022-02-04 |
| 2022-02-01 | 227669.83 | 未披露 | 定期报告 | 2022-01-28 |
| 2022-01-25 | 227726.33 | 未披露 | 定期报告 | 2022-01-21 |
| 2022-01-21 | 227779.57 | 未披露 | 定期报告 | 2022-01-14 |
| 2022-01-10 | 227834.57 | 未披露 | 定期报告 | 2022-01-10 |
| 2022-02-02 | 231000.00 | 未披露 | 定期报告 | 2021-12-31 |
| 2021-12-22 | 227890.07 | 未披露 | 定期报告 | 2021-12-21 |
| 2021-12-13 | 227958.47 | 未披露 | 定期报告 | 2021-12-10 |
| 2021-12-06 | 228009.14 | 未披露 | 定期报告 | 2021-12-03 |
| 2021-11-30 | 228060.73 | 未披露 | 定期报告 | 2021-11-26 |
| 2021-11-22 | 228110.73 | 未披露 | 定期报告 | 2021-11-19 |
| 2021-10-05 | 228905.89 | 未披露 | 定期报告 | 2021-10-01 |
| 2021-09-27 | 228949.36 | 未披露 | 定期报告 | 2021-09-24 |
| 2021-09-20 | 228989.56 | 未披露 | 定期报告 | 2021-09-17 |
| 2021-09-13 | 229029.21 | 未披露 | 定期报告 | 2021-09-10 |
| 2021-09-07 | 229069.81 | 未披露 | 定期报告 | 2021-09-03 |
| 2021-08-30 | 229110.21 | 未披露 | 定期报告 | 2021-08-27 |
| 2021-08-23 | 229150.21 | 未披露 | 定期报告 | 2021-08-20 |
| 2021-08-16 | 229190.31 | 未披露 | 定期报告 | 2021-08-13 |
| 2021-08-04 | 229244.71 | 未披露 | 定期报告 | 2021-08-03 |
| 2021-07-26 | 229314.06 | 未披露 | 定期报告 | 2021-07-23 |
| 2021-07-19 | 229365.56 | 未披露 | 定期报告 | 2021-07-12 |
| 2021-07-12 | 229420.56 | 未披露 | 定期报告 | 2021-07-09 |
| 2021-07-06 | 229475.25 | 未披露 | 定期报告 | 2021-07-02 |
| 2021-06-29 | 229529.25 | 未披露 | 定期报告 | 2021-06-25 |
| 2021-06-22 | 229578.98 | 未披露 | 定期报告 | 2021-06-18 |
| 2021-06-14 | 229629.48 | 未披露 | 定期报告 | 2021-06-07 |
| 2021-06-07 | 229682.98 | 未披露 | 定期报告 | 2021-05-31 |
| 2021-06-01 | 229737.98 | 未披露 | 定期报告 | 2021-05-25 |
| 2021-06-01 | 229782.37 | 未披露 | 定期报告 | 2021-05-17 |
| 2021-05-18 | 229841.77 | 未披露 | 定期报告 | 2021-05-12 |
| 2021-05-04 | 230434.26 | 未披露 | 定期报告 | 2021-04-26 |
| 2021-04-26 | 230488.51 | 未披露 | 定期报告 | 2021-04-19 |
| 2021-04-19 | 230545.01 | 未披露 | 定期报告 | 2021-04-12 |
| 2021-04-12 | 230603.04 | 未披露 | 定期报告 | 2021-03-29 |
| 2021-03-29 | 230684.54 | 未披露 | 定期报告 | 2021-03-22 |
| 2021-03-22 | 230742.54 | 未披露 | 定期报告 | 2021-03-19 |
| 2021-03-15 | 230798.84 | 未披露 | 定期报告 | 2021-03-08 |
| 2021-03-08 | 230854.34 | 未披露 | 定期报告 | 2021-03-05 |
| 2021-03-01 | 230912.21 | 未披露 | 定期报告 | 2021-02-26 |
| 2021-02-22 | 230966.84 | 未披露 | 定期报告 | 2021-02-15 |
| 2021-02-08 | 231076.83 | 未披露 | 定期报告 | 2021-02-08 |
| 2021-01-26 | 231073.63 | 未披露 | 定期报告 | 2021-01-26 |
| 2021-01-19 | 231126.13 | 未披露 | 定期报告 | 2021-01-19 |
| 2021-02-03 | 235000.00 | 未披露 | 定期报告 | 2020-12-31 |
| 2020-11-09 | 231613.31 | 未披露 | 定期报告 | 2020-11-06 |
| 2020-10-26 | 232375.26 | 未披露 | 定期报告 | 2020-10-26 |
| 2020-10-30 | 233510.00 | 未披露 |
更多>>
From January 1, 2020 to September 30, 2020
Purchase of treasury shares
Reduction of the B share capital
|
2020-09-30 |
| 2020-08-06 | 234490.00 | 未披露 | 定期报告 | 2020-06-30 |
| 2020-02-05 | 240000.00 | 未披露 | 定期报告 | 2019-12-31 |
| 2019-02-04 | 245000.00 | 未披露 | 定期报告 | 2018-12-31 |
| 2018-02-08 | 250000.00 | 未披露 | 定期报告 | 2017-12-31 |
| 2016-11-28 | 251009.89 | 未披露 | 定期报告 | 2016-11-28 |
| 2016-10-11 | 251946.84 | 未披露 | 定期报告 | 2016-10-07 |
| 2016-09-19 | 252245.34 | 未披露 | 定期报告 | 2016-09-12 |
| 2016-09-12 | 252340.84 | 未披露 | 定期报告 | 2016-09-05 |
| 2016-09-06 | 252443.94 | 未披露 | 定期报告 | 2016-09-02 |
| 2016-08-29 | 252538.54 | 未披露 | 定期报告 | 2016-08-26 |
| 2016-08-22 | 252632.04 | 未披露 | 定期报告 | 2016-08-19 |
| 2016-08-16 | 252720.64 | 未披露 | 定期报告 | 2016-08-12 |
| 2016-08-04 | 252828.24 | 未披露 | 定期报告 | 2016-08-01 |
| 2016-08-01 | 252870.24 | 未披露 | 定期报告 | 2016-07-29 |
| 2016-07-18 | 253007.24 | 未披露 | 定期报告 | 2016-07-15 |
| 2016-07-01 | 253162.24 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-02-10 | 260000.00 | 未披露 | 定期报告 | 2015-12-31 |
| 2015-02-05 | 265000.00 | 未披露 | 定期报告 | 2014-12-31 |
| 2014-05-06 | 263839.63 | 未披露 | 定期报告 | 2014-03-10 |
| 2014-03-11 | 263952.39 | 未披露 | 定期报告 | 2014-03-07 |
| 2014-03-04 | 264060.72 | 未披露 | 定期报告 | 2014-02-28 |
| 2014-02-24 | 264173.42 | 未披露 | 定期报告 | 2014-02-21 |
| 2014-02-18 | 264294.22 | 未披露 | 定期报告 | 2014-02-14 |
| 2014-01-29 | 264236.00 | 未披露 | 定期报告 | 2014-01-28 |
| 2014-01-21 | 264407.80 | 未披露 | 定期报告 | 2014-01-17 |
| 2014-02-05 | 264530.80 | 未披露 | 定期报告 | 2014-01-10 |
| 2013-12-10 | 264714.80 | 未披露 |
更多>>
On 2 January 2014, the Novo Nordisk A/S B shares traded on NASDAQ OMX Copenhagen will be split into five shares.
On 9 January 2014, each of Novo Nordisk’s ADRs listed on NYSE will also be split. On 8 January 2014, ADR holders of record as of 3 January 2014 will receive four additional ADRs per existing ADR. Hence, the ratio of B shares to ADRs listed on NYSE will remain 1:1. The new shares issued due to the split will be of the same type and class as the original shares.
|
2014-01-09 |
| 2013-12-30 | 52942.96 | 未披露 | 定期报告 | 2013-12-20 |
| 2013-12-17 | 52969.97 | 未披露 | 定期报告 | 2013-12-13 |
| 2013-12-09 | 52997.37 | 未披露 | 定期报告 | 2013-12-06 |
| 2013-12-02 | 53024.57 | 未披露 | 定期报告 | 2013-12-02 |
| 2013-11-20 | 53094.47 | 未披露 | 定期报告 | 2013-11-20 |
| 2013-11-25 | 53051.47 | 未披露 | 定期报告 | 2013-11-18 |
| 2013-10-30 | 53111.91 | 未披露 | 定期报告 | 2013-10-29 |
| 2013-10-22 | 53145.00 | 未披露 | 定期报告 | 2013-10-14 |
| 2013-10-31 | 53166.30 | 未披露 | 定期报告 | 2013-10-11 |
| 2013-10-07 | 53189.50 | 未披露 | 定期报告 | 2013-10-04 |
| 2013-10-02 | 53210.70 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-09-26 | 53238.40 | 未披露 | 定期报告 | 2013-09-20 |
| 2013-09-17 | 53260.00 | 未披露 | 定期报告 | 2013-09-13 |
| 2013-09-10 | 53281.40 | 未披露 | 定期报告 | 2013-09-02 |
| 2013-09-03 | 53303.40 | 未披露 | 定期报告 | 2013-08-30 |
| 2013-09-04 | 53324.50 | 未披露 | 定期报告 | 2013-08-23 |
| 2013-08-20 | 53343.73 | 未披露 | 定期报告 | 2013-08-16 |
| 2013-08-07 | 53368.21 | 未披露 | 定期报告 | 2013-08-06 |
| 2013-09-04 | 53404.73 | 未披露 | 定期报告 | 2013-07-26 |
| 2013-07-23 | 53429.23 | 未披露 | 定期报告 | 2013-07-19 |
| 2013-07-15 | 53454.23 | 未披露 | 定期报告 | 2013-07-12 |
| 2013-07-08 | 53479.23 | 未披露 | 定期报告 | 2013-07-05 |
| 2013-07-05 | 53502.33 | 未披露 | 定期报告 | 2013-06-28 |
| 2013-06-24 | 53527.03 | 未披露 | 定期报告 | 2013-06-21 |
| 2013-06-18 | 53554.63 | 未披露 | 定期报告 | 2013-06-14 |
| 2013-06-10 | 53578.13 | 未披露 | 定期报告 | 2013-06-03 |
| 2013-06-04 | 53598.59 | 未披露 | 定期报告 | 2013-05-31 |
| 2013-05-28 | 53625.79 | 未披露 | 定期报告 | 2013-05-24 |
| 2013-05-22 | 53649.69 | 未披露 | 定期报告 | 2013-05-17 |
| 2013-05-13 | 53672.60 | 未披露 | 定期报告 | 2013-05-08 |
| 2013-04-15 | 53991.95 | 未披露 | 定期报告 | 2013-04-12 |
| 2013-03-18 | 54080.12 | 未披露 | 定期报告 | 2013-03-15 |
| 2013-02-06 | 56000.00 | 未披露 | 定期报告 | 2012-12-31 |
| 2012-04-26 | 55189.83 | 未披露 | 定期报告 | 2012-04-17 |
| 2012-04-24 | 55250.54 | 未披露 | 定期报告 | 2012-04-02 |
| 2012-04-03 | 55267.04 | 未披露 | 定期报告 | 2012-03-30 |
| 2012-03-28 | 55295.04 | 未披露 | 定期报告 | 2012-03-23 |
| 2012-03-20 | 55322.74 | 未披露 | 定期报告 | 2012-03-12 |
| 2012-03-06 | 55375.88 | 未披露 | 定期报告 | 2012-02-27 |
| 2012-02-14 | 55449.67 | 未披露 |
更多>>
Since the announcement as of 2 February 2012, the transactions have been made under the programme
|
2012-02-13 |
| 2012-02-01 | 55399.27 | 未披露 |
更多>>
Since the announcement as of 23 January 2012, transactions have been made under the programme.
|
2012-02-01 |
| 2012-01-17 | 55486.87 | 未披露 |
更多>>
Since the announcement as of 9 January 2012, transactions have been made under the programme
|
2012-01-16 |
| 2012-01-11 | 55522.48 | 未披露 |
更多>>
Since the announcement as of 2 January 2012, transactions have been made under the programme
|
2012-01-09 |
| 2012-02-06 | 58000.00 | 未披露 | 定期报告 | 2011-12-31 |
| 2012-01-03 | 55555.98 | 未披露 |
更多>>
Since the announcement as of 27 December 2011, transactions have been made under the programme
|
2011-12-27 |
| 2011-12-28 | 55575.98 | 未披露 |
更多>>
Since the announcement as of 19 December 2011,transactions have been made under the programme
|
2011-12-19 |
| 2011-12-21 | 55581.81 | 未披露 |
更多>>
Since the announcement as of 12 December 2011,transactions have been made under the programme
|
2011-12-12 |
| 2011-02-14 | 60000.00 | 未披露 | 定期报告 | 2010-12-31 |
| 2010-02-11 | 62000.00 | 未披露 | 定期报告 | 2009-12-31 |
| 2009-02-09 | 63400.00 | 未披露 | 定期报告 | 2008-12-31 |
| 2008-02-11 | 62114.49 | 未披露 | 定期报告 | 2007-12-31 |
| 2007-02-09 | 31724.69 | 未披露 | 定期报告 | 2006-12-31 |
| 2006-02-06 | 32371.49 | 未披露 | 定期报告 | 2005-12-31 |
| 2005-02-23 | 33210.90 | 未披露 | 定期报告 | 2004-12-31 |
| 2004-02-27 | 33815.13 | 未披露 | 定期报告 | 2003-12-31 |
| 2003-03-27 | 34529.73 | 未披露 | 定期报告 | 2002-12-31 |
As communicated on 10 August 2023 in connection with the release of Novo Nordisk's financial results for the first six months of 2023, Novo Nordisk's Board of Directors has approved a split of the trading units of the Novo Nordisk B shares listed on Nasdaq Copenhagen and of the American Depositary Receipts (ADRs) listed on New York Stock Exchange (NYSE) in a two-for-one ratio.
From December 31, 2021 to December 31, 2022
Purchase of treasury shares
Reduction of the B share capital
From January 1, 2020 to September 30, 2020
Purchase of treasury shares
Reduction of the B share capital
On 2 January 2014, the Novo Nordisk A/S B shares traded on NASDAQ OMX Copenhagen will be split into five shares.
On 9 January 2014, each of Novo Nordisk’s ADRs listed on NYSE will also be split. On 8 January 2014, ADR holders of record as of 3 January 2014 will receive four additional ADRs per existing ADR. Hence, the ratio of B shares to ADRs listed on NYSE will remain 1:1. The new shares issued due to the split will be of the same type and class as the original shares.
Since the announcement as of 2 February 2012, the transactions have been made under the programme
Since the announcement as of 23 January 2012, transactions have been made under the programme.
Since the announcement as of 9 January 2012, transactions have been made under the programme
Since the announcement as of 2 January 2012, transactions have been made under the programme
Since the announcement as of 27 December 2011, transactions have been made under the programme
Since the announcement as of 19 December 2011,transactions have been made under the programme
Since the announcement as of 12 December 2011,transactions have been made under the programme